PharmiWeb Recruiter Blog

Chicago, IL (May 25, 2023) — Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a biopharmaceutical industry-first collaboration with StuffThatWorks, the first data-driven community platform that uses crowdsourcing and AI to transform patient journeys and health metrics into actionable real world data in an effort to streamline research and bring clinical research closer to patients and caregivers.

Company receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues

DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been rated the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated.

Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.

• Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales.
• Life Edit has the option to a global profit share on one programme.
• Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing.

Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets.

• Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.
• Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
• Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.
• Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.

Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames.

• Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies.
• Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach.
• The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development. 

CARY, N.C., May 23, 2023 – Global biopharmaceutical services provider Allucent announced today that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials. The new offering brings advanced technologies and development and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial approaches that address their needs.

• The Oxford-based company has relocated to the landmark Seacourt Tower in Botley, upgrading its office space to accommodate its growing team of AI specialists

OXFORD, UK, 15 May 2023 – Brainomix, the AI-powered medtech solutions company, today announced it has moved to a new head office in Oxford, located in the landmark Seacourt Tower in Botley.

• New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
• Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
• The new programs build on a successful first year of the multi-million-dollar corporate initiative

ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

• Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology
• Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals
• Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered commercial royalties

BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle^®), today announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets.

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors –